JACOBSON PHARMA (02633) announces profit growth, expected to increase by over 10% year-on-year for the 2025 fiscal year.

JACOBSON PHARMA (02633) announced that the Group expects a year-on-year increase of over 40% in net profit from its continuing operations for the year ending March 31, 2025. This is mainly attributed to the strong performance of specialty drugs and the overall non-patent drug business, as well as the revenue contribution from newly authorized products and strong launches of new products. In addition, the improvement in operating leverage of production facilities and corresponding savings in expenses due to effective cost control measures are also driving the growth. Following the physical distribution of JBM HEALTHCARE (02161) shares to shareholders as a special dividend in August 2023, the company will no longer consolidate the results of JBM HEALTHCARE and its subsidiaries in its financial statements. Therefore, it is expected that the net profit attributable to equity holders of the company for the 2025 financial year will increase by over 10% year-on-year.